[{"orgOrder":0,"company":"Vaxine","sponsor":"Medytox","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVAX-19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Vaxine \/ Medytox Inc","highestDevelopmentStatusID":"4","companyTruncated":"Vaxine \/ Medytox Inc"},{"orgOrder":0,"company":"Vaxine","sponsor":"CinnaGen Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Advax-SM","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxine \/ Vaxine","highestDevelopmentStatusID":"10","companyTruncated":"Vaxine \/ Vaxine"},{"orgOrder":0,"company":"Vaxine","sponsor":"Prestige BioPharma Pte Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Covax-19","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Vaxine \/ Vaxine Pty Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Vaxine \/ Vaxine Pty Ltd"}]

Find Clinical Drug Pipeline Developments & Deals by Vaxine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Through MOU, Prestige and Vaxine will be building a partnership, initially focused on manufacturing and commercialization of Vaxine’s Covid-19 vaccine, Covax-19® and then as Covid-19 enters an endemic phase development of a next generation Covid19/inf...

                          Brand Name : Spikogen

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          March 30, 2022

                          Lead Product(s) : Covax-19

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Recipient : Prestige BioPharma Pte Ltd

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : SpikoGen features the SARS-CoV-2 spike protein and Vaxine’s own Advax-SM adjuvant. The placebo-controlled SpikoGen trial has coprimary endpoints investigating the occurrence of symptomatic Covid-19 and severe Covid-19, with both endpoints.

                          Brand Name : SpikoGen

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          September 16, 2021

                          Lead Product(s) : SARS-CoV-2 Recombinant Spike Protein,Advax-SM

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : CinnaGen Co

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The collaboration aims at developing a Covid-19 vaccine called, COVAX-19®, which is currently undergoing late stage animal testing and is based on Vaxine’s proprietary Advax™ adjuvant technology combined with a recombinant SARS-CoV-2 spike protein.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          May 25, 2020

                          Lead Product(s) : COVAX-19

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Medytox

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank